Eagle Pharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- Eagle Pharmaceuticals's estimated annual revenue is currently $43.5M per year.
- Eagle Pharmaceuticals's estimated revenue per employee is $251,250
- Eagle Pharmaceuticals's total funding is $12.3M.
Employee Data
- Eagle Pharmaceuticals has 173 Employees.
- Eagle Pharmaceuticals grew their employee count by 26% last year.
Eagle Pharmaceuticals's People
Name | Title | Email/Phone |
---|---|---|
1 | EVP, General Counsel & Chief Compliance Officer | Reveal Email/Phone |
2 | Head Commercial for Acute Care/Hospital | Reveal Email/Phone |
3 | VP, Market Access, Oncology | Reveal Email/Phone |
4 | Head Commercial for Acute Care/Hospital | Reveal Email/Phone |
5 | EVP, Oncology Business Development | Reveal Email/Phone |
6 | VP Pharmaceutical Sciences | Reveal Email/Phone |
7 | EVP Oncology & Acute Care Marketing | Reveal Email/Phone |
8 | SVP, Pharmaceutical Development | Reveal Email/Phone |
9 | SVP, Oncology Accounts | Reveal Email/Phone |
10 | SVP, Hospital Sales and Marketing | Reveal Email/Phone |
Eagle Pharmaceuticals Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $5M | 25 | -11% | N/A | N/A |
#2 | $35.8M | 178 | 8% | N/A | N/A |
#3 | $5.4M | 27 | -25% | N/A | N/A |
#4 | $4180M | 14516 | 1% | $550M | N/A |
#5 | $12.5M | 62 | 15% | N/A | N/A |
#6 | $6.7M | 119 | -37% | $199.6M | N/A |
#7 | $9.4M | 47 | 7% | N/A | N/A |
#8 | $10.3M | 51 | 6% | N/A | N/A |
#9 | $106.3M | 529 | 16% | N/A | N/A |
#10 | $15.5M | 77 | 20% | N/A | N/A |
What Is Eagle Pharmaceuticals?
Eagle Pharmaceuticals is a specialty pharmaceutical company focused on developing and commercializing injectable products, primarily in the critical care and oncology areas, using the 505(b)(2) regulatory pathway. Our business model is to develop proprietary innovations to FDA-approved, injectable drugs, which we refer to as branded listed drugs, that offer longer commercial duration provided by orphan drug exclusivity, new intellectual property protection, and/or three years of non-patent regulatory exclusivity as provided under the Drug Price Competition and Patent Term Restoration Act of 1984, or the Hatch Waxman Act.
keywords:N/A$12.3M
Total Funding
173
Number of Employees
$43.5M
Revenue (est)
26%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Eagle Pharmaceuticals News
About Eagle Pharmaceuticals, Inc. Eagle is a fully integrated pharmaceutical company with research and development, clinical, manufacturing and...
EAGLE PHARMACEUTICALS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K). Link copied. 04/27/2022 | 06:14am...
Eagle is a fully integrated pharmaceutical company with research and development, clinical, manufacturing and commercial expertise. Eagle is...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $31.1M | 283 | 6% | N/A |
#2 | $131M | 422 | -1% | N/A |
#3 | $100.2M | 553 | -3% | N/A |
#4 | $367M | 749 | 8% | N/A |
#5 | $1216M | 2632 | 7% | N/A |